← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT06427707

NCT06427707 The Effect of Adding Either Propofol or Ketamine to Magnesium and Lidocaine Infusions in Nasal Surgeries.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06427707
Status Recruiting
Phase Phase 2, Phase 3
Sponsor Ain Shams University
Condition Intraoperative Bleeding
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2024-06-15
Primary Completion 2024-10-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Intravenous Infusion of propofol, lidocaine, Magnesium sulfateIntravenous infusion of ketamine, lidocaine, Magnesium sulfateIntravenous infusion of dexmedetomidine, lidocaine, Magnesium sulfate

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 90 participants in total. It began in 2024-06-15 with a primary completion date of 2024-10-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Nasal surgeries are common day case procedures. Although surgical complications are rare, bleeding decreases surgical field visibility and may cause vascular, orbital or intracranial complications in addition to failure of procedure. So, it is crucial to maintain hypotensive anaesthesia to optimize the surgical field.

Eligibility Criteria

Inclusion Criteria: * ASA I-II, * scheduled for elective nasal surgery Exclusion Criteria: * Patients with uncontrolled hypertension. * Patients with cardiac disease. * Patients with renal, hepatic or cerebral insufficiency. * Patients with coagulopathy or receiving drugs influencing blood coagulation. * Anaemia, haemoglobinopathies or polycythemia. * Pregnancy. * Patients with known sensitivity to any of the study drug.

Contact & Investigator

Central Contact

RANIA M Hussien, MD

✉ drrania_maamon@med.asu.edu.eg

📞 01000544520

Frequently Asked Questions

Who can join the NCT06427707 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Intraoperative Bleeding. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06427707 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06427707 currently recruiting?

Yes, NCT06427707 is actively recruiting participants. Contact the research team at drrania_maamon@med.asu.edu.eg for enrollment information.

Where is the NCT06427707 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06427707 clinical trial?

NCT06427707 is sponsored by Ain Shams University. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology